Role of 6% hydroxyethylstarch 130/0.4 and furosemide in the treatment of acute pancreatitis / 生物医学工程学杂志
Journal of Biomedical Engineering
; (6): 1138-1145, 2010.
Article
em Zh
| WPRIM
| ID: wpr-260923
Biblioteca responsável:
WPRO
ABSTRACT
This study was conducted to observe the effects of intravenously administered 6% hydroxyethylstarch 130/ 0.4 solution and furosemide on the outcome of acute pancreatitis patients. Patients admitted to our center from October 16, 2007 through August 31, 2009 were given intravenous infusions of 6% hydroxyethylstarch 130/0. 4 solution (1 000-2 000 ml administered for an adult) soon after admission. At the same time, furosemide was administered as intravenous bolus, trying to maintain a fluid balance. The dose level of hydroxyethylstarch was gradually lowered from the second day after admission. A total of 135 patients (54% of patients with a Ranson's score > or = 3 and 61% with a Balthazar CT score > or = D) were treated with our protocol. Only 4% and 7% patients developed pancreatic and systemic complications respectively; only 1 patient underwent necrosectomy. The in-hospital mortality rate was 4%. It was estimated that, on the average, 18. 3% of blood volume was lost on admission. Our study suggest that intravenously administered 6% hydroxyethylstarch 130/0. 4 solution and furosemide might be beneficial for patients with acute pancreatitis. Plasma extravasation is a central event of acute pancreatitis. The reversal of hypovolemia is crucial for the success in treatment of acute pancreatitis.
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Pancreatite
/
Infusões Intravenosas
/
Doença Aguda
/
Derivados de Hidroxietil Amido
/
Hipovolemia
/
Tratamento Farmacológico
/
Furosemida
/
Injeções Intravenosas
Tipo de estudo:
Guideline
Limite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Idioma:
Zh
Revista:
Journal of Biomedical Engineering
Ano de publicação:
2010
Tipo de documento:
Article